Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8.

Science immunology

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C.
PMID: 28367538
Sci Immunol. 2017 Feb;2(8). doi: 10.1126/sciimmunol.aal2568. Epub 2017 Feb 24.

Adoptively transferred tumor-specific cells can mediate tumor regression in cancers refractory to conventional therapy. Autologous polyclonal tumor-specific cytotoxic T cells (CTL) generated from peripheral blood and infused into patients with metastatic melanoma show enhanced persistence, compared to equivalent numbers...

Cite
Chapuis AG, Desmarais C, Emerson R, et al. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Sci Immunol. 2017;2(8)doi: 10.1126/sciimmunol.aal2568.
Chapuis, A. G., Desmarais, C., Emerson, R., Schmitt, T. M., Shibuya, K., Lai, I., Wagener, F., Chou, J., Roberts, I. M., Coffey, D. G., Warren, E., Robbins, H., Greenberg, P. D., & Yee, C. (2017). Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Science immunology, 2(8), . https://doi.org/10.1126/sciimmunol.aal2568
Chapuis, Aude G, et al. "Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8." Science immunology vol. 2,8 (2017). doi: https://doi.org/10.1126/sciimmunol.aal2568
Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Sci Immunol. 2017 Feb;2(8). doi: 10.1126/sciimmunol.aal2568. Epub 2017 Feb 24. PMID: 28367538; PMCID: PMC5371351.
Copy Download .nbib Format: NLM
Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation.

Mediterranean journal of hematology and infectious diseases

Sorror ML, Storb RF.
PMID: 21152378
Mediterr J Hematol Infect Dis. 2010;2(2):e2010015. doi: 10.4084/MJHID.2010.015. Epub 2010 Jun 09.

Allogeneic conventional hematopoietic cell transplantation (HCT) following high-dose, myeloablative conditioning regimens has been used since the 1970's as potentially curative treatment for patients with malignant, hematological disorders. The toxicities of conditioning regimens have limited conventional HCT to relatively young...

Cite
Sorror ML, Storb RF. Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2010;2(2):e2010015doi: 10.4084/MJHID.2010.015.
Sorror, M. L., & Storb, R. F. (2010). Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation. Mediterranean journal of hematology and infectious diseases, 2(2), e2010015. https://doi.org/10.4084/MJHID.2010.015
Sorror, Mohamed L, and Storb, Rainer F. "Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation." Mediterranean journal of hematology and infectious diseases vol. 2,2 (2010): e2010015. doi: https://doi.org/10.4084/MJHID.2010.015
Sorror ML, Storb RF. Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2010;2(2):e2010015. doi: 10.4084/MJHID.2010.015. Epub 2010 Jun 09. PMID: 21152378; PMCID: PMC2997746.
Copy Download .nbib Format: NLM
Cytomegalovirus in hematopoietic stem cell transplant recipients.

Hematology/oncology clinics of North America

Ljungman P, Hakki M, Boeckh M.
PMID: 21236396
Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011.

This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined.

Cite
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151-69doi: 10.1016/j.hoc.2010.11.011.
Ljungman, P., Hakki, M., & Boeckh, M. (2011). Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematology/oncology clinics of North America, 25(1), 151-69. https://doi.org/10.1016/j.hoc.2010.11.011
Ljungman, Per, et al. "Cytomegalovirus in hematopoietic stem cell transplant recipients." Hematology/oncology clinics of North America vol. 25,1 (2011): 151-69. doi: https://doi.org/10.1016/j.hoc.2010.11.011
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011. PMID: 21236396; PMCID: PMC3340426.
Copy Download .nbib Format: NLM
Hematopoietic Cell Transplantation for Older Patients with MDS.

Mediterranean journal of hematology and infectious diseases

Shadman M, Deeg HJ.
PMID: 25237469
Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014056. doi: 10.4084/MJHID.2014.056. eCollection 2014.

The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age. While several therapeutic modalities have been developed, for most of these patients the only treatment with curative potential is allogeneic hematopoietic cell transplantation (HCT). The development of...

Cite
Shadman M, Deeg HJ. Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis. 2014;6(1):e2014056doi: 10.4084/MJHID.2014.056.
Shadman, M., & Deeg, H. J. (2014). Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterranean journal of hematology and infectious diseases, 6(1), e2014056. https://doi.org/10.4084/MJHID.2014.056
Shadman, Mazyar, and Deeg, H Joachim. "Hematopoietic Cell Transplantation for Older Patients with MDS." Mediterranean journal of hematology and infectious diseases vol. 6,1 (2014): e2014056. doi: https://doi.org/10.4084/MJHID.2014.056
Shadman M, Deeg HJ. Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014056. doi: 10.4084/MJHID.2014.056. eCollection 2014. PMID: 25237469; PMCID: PMC4165501.
Copy Download .nbib Format: NLM
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Journal for immunotherapy of cancer

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.
PMID: 25317334
J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

BACKGROUND: Adoptive T cell therapy represents an attractive modality for the treatment of patients with cancer. Peripheral blood mononuclear cells have been used as a source of antigen specific T cells but the very low frequency of T cells...

Cite
Pollack SM, Jones RL, Farrar EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014;2(1):36doi: 10.1186/s40425-014-0036-y.
Pollack, S. M., Jones, R. L., Farrar, E. A., Lai, I. P., Lee, S. M., Cao, J., Pillarisetty, V. G., Hoch, B. L., Gullett, A., Bleakley, M., Conrad, E. U., Eary, J. F., Shibuya, K. C., Warren, E. H., Carstens, J. N., Heimfeld, S., Riddell, S. R., & Yee, C. (2014). Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. Journal for immunotherapy of cancer, 2(1), 36. https://doi.org/10.1186/s40425-014-0036-y
Pollack, Seth M, et al. "Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells." Journal for immunotherapy of cancer vol. 2,1 (2014): 36. doi: https://doi.org/10.1186/s40425-014-0036-y
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014. PMID: 25317334; PMCID: PMC4196009.
Copy Download .nbib Format: NLM
Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation.

Blood

Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ.
PMID: 34269803
Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153.

Human cytomegalovirus (CMV) reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Despite routine screening for CMV reactivation and early antiviral treatment, the rates of CMV-related complications after HCT remain high. Genetic variants in both the donor...

Cite
Casto AM, Seo S, Levine DM, et al. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021;138(17):1628-1636doi: 10.1182/blood.2021012153.
Casto, A. M., Seo, S., Levine, D. M., Storer, B. E., Dong, X., Hansen, J. A., Boeckh, M., & Martin, P. J. (2021). Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood, 138(17), 1628-1636. https://doi.org/10.1182/blood.2021012153
Casto, Amanda M, et al. "Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation." Blood vol. 138,17 (2021): 1628-1636. doi: https://doi.org/10.1182/blood.2021012153
Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153. PMID: 34269803; PMCID: PMC8554648.
Copy Download .nbib Format: NLM
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.

Bone marrow transplantation

Yeh AC, O'Donnell PV, Schoch G, Martin PJ, McFarland C, McCune JS, Cooper JP, Doney K, Flowers MED, Sorror ML, Appelbaum FR, Storer BE, Gooley T, Deeg HJ.
PMID: 34741096
Bone Marrow Transplant. 2021 Nov 05; doi: 10.1038/s41409-021-01518-0. Epub 2021 Nov 05.

We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n = 23] or 250 [n = 17] mg/m

Cite
Yeh AC, O'Donnell PV, Schoch G, et al. Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplant. 2021;doi: 10.1038/s41409-021-01518-0.
Yeh, A. C., O'Donnell, P. V., Schoch, G., Martin, P. J., McFarland, C., McCune, J. S., Cooper, J. P., Doney, K., Flowers, M. E. D., Sorror, M. L., Appelbaum, F. R., Storer, B. E., Gooley, T., & Deeg, H. J. (2021). Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone marrow transplantation, . https://doi.org/10.1038/s41409-021-01518-0
Yeh, Albert C, et al. "Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin." Bone marrow transplantation vol. (2021). doi: https://doi.org/10.1038/s41409-021-01518-0
Yeh AC, O'Donnell PV, Schoch G, Martin PJ, McFarland C, McCune JS, Cooper JP, Doney K, Flowers MED, Sorror ML, Appelbaum FR, Storer BE, Gooley T, Deeg HJ. Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplant. 2021 Nov 05; doi: 10.1038/s41409-021-01518-0. Epub 2021 Nov 05. PMID: 34741096.
Copy Download .nbib Format: NLM
An Application of Stream Imaging Technique in the Study of Osmotic Behaviors of Multiple Cells.

Cell preservation technology

Chen HH, Lin EH, Heimfeld S, Gao D.
PMID: 20523753
Cell Preserv Technol. 2008 Jun 01;6(2):125-132. doi: 10.1089/cpt.2008.0002.

Light microscopy method offers unique abilities for the determination of membrane transport properties of either single or multiple cells. A stream imaging system composed of a microfluidic device, a charge-coupled device camera, and a microscope has been developed to...

Cite
Chen HH, Lin EH, Heimfeld S, et al. An Application of Stream Imaging Technique in the Study of Osmotic Behaviors of Multiple Cells. Cell Preserv Technol. 2008;6(2):125-132doi: 10.1089/cpt.2008.0002.
Chen, H. H., Lin, E. H., Heimfeld, S., & Gao, D. (2008). An Application of Stream Imaging Technique in the Study of Osmotic Behaviors of Multiple Cells. Cell preservation technology, 6(2), 125-132. https://doi.org/10.1089/cpt.2008.0002
Chen, Hsiu-Hung, et al. "An Application of Stream Imaging Technique in the Study of Osmotic Behaviors of Multiple Cells." Cell preservation technology vol. 6,2 (2008): 125-132. doi: https://doi.org/10.1089/cpt.2008.0002
Chen HH, Lin EH, Heimfeld S, Gao D. An Application of Stream Imaging Technique in the Study of Osmotic Behaviors of Multiple Cells. Cell Preserv Technol. 2008 Jun 01;6(2):125-132. doi: 10.1089/cpt.2008.0002. PMID: 20523753; PMCID: PMC2879654.
Copy Download .nbib Format: NLM
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Leukemia research and treatment

Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U.
PMID: 26783469
Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. Epub 2015 Dec 10.

Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care...

Cite
Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leuk Res Treatment. 2015;2015:982395doi: 10.1155/2015/982395.
Rochau, U., Kluibenschaedl, M., Stenehjem, D., Kuan-Ling, K., Radich, J., Oderda, G., Brixner, D., & Siebert, U. (2015). Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leukemia research and treatment, 2015982395. https://doi.org/10.1155/2015/982395
Rochau, Ursula, et al. "Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis." Leukemia research and treatment vol. 2015 (2015): 982395. doi: https://doi.org/10.1155/2015/982395
Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. Epub 2015 Dec 10. PMID: 26783469; PMCID: PMC4689963.
Copy Download .nbib Format: NLM
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.

JCI insight

Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, Hill JA.
PMID: 33914708
JCI Insight. 2021 Jun 08;6(11). doi: 10.1172/jci.insight.146743.

BACKGROUNDLittle is known about pathogen-specific humoral immunity after chimeric antigen receptor-modified T (CAR-T) cell therapy for B cell malignancies.METHODSWe conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen-targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6...

Cite
Walti CS, Krantz EM, Maalouf J, et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021;6(11)doi: 10.1172/jci.insight.146743.
Walti, C. S., Krantz, E. M., Maalouf, J., Boonyaratanakornkit, J., Keane-Candib, J., Joncas-Schronce, L., Stevens-Ayers, T., Dasgupta, S., Taylor, J. J., Hirayama, A. V., Bar, M., Gardner, R. A., Cowan, A. J., Green, D. J., Boeckh, M. J., Maloney, D. G., Turtle, C. J., & Hill, J. A. (2021). Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI insight, 6(11), . https://doi.org/10.1172/jci.insight.146743
Walti, Carla S, et al. "Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies." JCI insight vol. 6,11 (2021). doi: https://doi.org/10.1172/jci.insight.146743
Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, Hill JA. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021 Jun 08;6(11). doi: 10.1172/jci.insight.146743. PMID: 33914708; PMCID: PMC8262349.
Copy Download .nbib Format: NLM
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy.

medRxiv : the preprint server for health sciences

Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA.
PMID: 34013294
medRxiv. 2021 May 11; doi: 10.1101/2021.05.10.21256634.

Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B-cell malignancies are immunocompromised and at risk for serious infections. Vaccine immunogenicity is unknown in this population. We conducted a prospective observational study of the humoral immunogenicity of 2019-2020...

Cite
Walti CS, Loes AN, Shuey K, et al. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv. 2021;doi: 10.1101/2021.05.10.21256634.
Walti, C. S., Loes, A. N., Shuey, K., Krantz, E. M., Boonyaratanakornkit, J., Keane-Candib, J., Loeffelholz, T., Wolf, C. R., Taylor, J. J., Gardner, R. A., Green, D. J., Cowan, A. J., Maloney, D. G., Turtle, C. J., Pergam, S. A., Chu, H. Y., Bloom, J. D., & Hill, J. A. (2021). Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.05.10.21256634
Walti, Carla S, et al. "Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.05.10.21256634
Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv. 2021 May 11; doi: 10.1101/2021.05.10.21256634. PMID: 34013294; PMCID: PMC8132269.
Copy Download .nbib Format: NLM
Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant.

Journal of cancer survivorship : research and practice

Wu NL, Krull KR, Cushing-Haugen KL, Ullrich NJ, Kadan-Lottick NS, Lee SJ, Chow EJ, Craig SD, Hu X, Graesser AC, Bargagliotti AE.
PMID: 34086185
J Cancer Surviv. 2021 Jun 04; doi: 10.1007/s11764-021-01063-1. Epub 2021 Jun 04.

PURPOSE: Pediatric patients who undergo hematopoietic cell transplant (HCT) are at risk for neurocognitive impairments, which can impact quality of life. Given limited long-term studies, we aimed to characterize the late neurocognitive outcomes in a cohort of pediatric HCT...

Cite
Wu NL, Krull KR, Cushing-Haugen KL, et al. Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. J Cancer Surviv. 2021;doi: 10.1007/s11764-021-01063-1.
Wu, N. L., Krull, K. R., Cushing-Haugen, K. L., Ullrich, N. J., Kadan-Lottick, N. S., Lee, S. J., Chow, E. J., Craig, S. D., Hu, X., Graesser, A. C., & Bargagliotti, A. E. (2021). Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. Journal of cancer survivorship : research and practice, . https://doi.org/10.1007/s11764-021-01063-1
Wu, Natalie L, et al. "Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant." Journal of cancer survivorship : research and practice vol. (2021). doi: https://doi.org/10.1007/s11764-021-01063-1
Wu NL, Krull KR, Cushing-Haugen KL, Ullrich NJ, Kadan-Lottick NS, Lee SJ, Chow EJ, Craig SD, Hu X, Graesser AC, Bargagliotti AE. Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. J Cancer Surviv. 2021 Jun 04; doi: 10.1007/s11764-021-01063-1. Epub 2021 Jun 04. PMID: 34086185; PMCID: PMC8642486.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries